At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,145 enrolled
Drug / intervention
bevacizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab Therapy With or Without Erlotinib After Completion of Chemotherapy With Bevacizumab for the First-Line Treatment of Locally Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer
In Brief
A Phase 3 clinical trial evaluating bevacizumab, placebo, and 1 other intervention for Non-Small Cell Lung Cancer. Completed, enrolled 1,145 participants across 247 sites in 17 countries.
Detailed Summary
This is a Phase IIIb, multicenter, randomized, placebo-controlled trial to evaluate the safety and efficacy of chemotherapy+bevacizumab followed by bevacizumab+erlotinib versus bevacizumab+erlotinib placebo in subjects with locally advanced or metastatic NSCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesArgentina, Australia, Belgium, Brazil, Bulgaria, Hong Kong, Israel, Italy, Mexico, Philippines, Romania, Singapore, Spain, Taiwan, Thailand, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2005
Enrollment StartJan 2006
Primary CompletionNov 2014
TodayJul 2026
First PostedNov 23, 2005
Enrollment StartJan 1, 2006
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8.8 yearsPosted 20.6 years ago
Interventions
bevacizumabdrug
Intravenous repeating dose
placebodrug
Oral repeating dose
erlotinib HCldrug
Oral repeating dose